tousled1
12-16-2007, 12:49 PM
GlaxoSmithKline Plc announced further clinical trial results on Sunday underlining the ability of a drug combination including its product Tykerb to fight breast cancer that has spread to the brain.
An extension to an earlier Phase II study involving 49 patients showed 20 percent of those receiving a mix of Tykerb and Roche's Xeloda experienced at least a 50 percent volume reduction in measurable brain metastases.
Full article: http://www.reuters.com/article/healthNews/idUSL1464852720071216
An extension to an earlier Phase II study involving 49 patients showed 20 percent of those receiving a mix of Tykerb and Roche's Xeloda experienced at least a 50 percent volume reduction in measurable brain metastases.
Full article: http://www.reuters.com/article/healthNews/idUSL1464852720071216